Skip to content

Tenon Medical CATAMARAN™ SI Joint Fusion System CT Scan Study

Prospective, Multi-Center, Single Arm Post-Market Study of the Tenon Medical CATAMARAN™ SI Joint Fusion System.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05628142
Enrollment
50
Registered
2022-11-28
Start date
2022-11-01
Completion date
2024-11-30
Last updated
2023-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative Sacroiliitis, Sacroiliac Joint Disruption

Brief summary

The objective of this study is to evaluate 6-to-12-month radiographic outcomes of patients with sacroiliac joint disruptions or degenerative sacroiliitis that have already undergone treatment with the CATAMARAN SI Joint Fusion System. In addition, retrospective and prospective clinical outcomes will be evaluated.

Detailed description

Patients with degenerative sacroiliitis or sacroiliac joint disruption who already had the CATAMARAN Fixation Device implanted between 6 and 12 months will be asked to return for follow-up visit to evaluate clinical outcomes and undergo a high resolution pelvic CT-Scan to assess fusion. Additionally, retrospective clinical outcomes will be collected from the medical records.

Interventions

RADIATIONPelvic CT Scan

Pelvic CT-Scan between 6-12 months post-op

Sponsors

Tenon Medical
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient \>18 years of age at time of treatment with the CATAMARAN SI Joint Fusion System * Patient implanted with the CATAMARAN Fixation Device within the last 12 months * Diagnosis of sacroiliac joint disruption or degenerative sacroiliitis * Patient, or authorized representative, signs a written Informed Consent form to participate in the study * Patient is willing and able to complete study follow-up requirements

Exclusion criteria

* Known or suspected active drug or alcohol abuse * Previously diagnosed osteoporosis (defined as prior T-score \<-2.5 or history of osteoporotic fracture) or prior/current use of drug therapy for osteoporosis. * Prior fracture of any bone related to cancer/tumor (i.e., pathologic fracture) * Prior diagnosis of tumor in sacrum or ilium * Unstable fracture of sacrum and or ilium involving the targeted SIJ * Osteomalacia or other metabolic bone disease * Use of medications known to have detrimental effects on bone quality and soft-tissue healing * Patient is pregnant or wishes to become pregnant during the study period * Patient is not likely to comply with the follow-up evaluation schedule * Patient is a prisoner or a ward of the state

Design outcomes

Primary

MeasureTime frameDescription
Radiographic Fusion6-12 month post CATAMARAN Fixation Device implantationThe primary endpoint is the proportion of subjects that demonstrate radiographic fusion assessed by CT-Scan, as evaluated by an Independent Radiologist.

Secondary

MeasureTime frameDescription
Device Status6-12 months post-opRadiographic assessment for device status: device placement, loosening, migration and/or breakage
Surgical re-intervention for SI joint pain6-12 months post-opProportion of patients requiring surgical re-intervention (removal, revision, reoperation, or supplemental fixation) for SI joint pain
Neurologic worsening related to the sacral spine6-12 months post-opProportion of patients experiencing neurologic worsening related to the sacral spine compared to baseline
Serious device related adverse events6-12 months post-opSummary of all serious device related adverse events

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026